Rituximab: A useful drug for a repreatedly relapsed hairy cell leukemia patient

Annals of Hematology

Volumn 81, Issue 12, 2002, Pages 736-738

  Pollio, F ^a   Pocali, B ^a   Palmieri, S ^a   Morabito, P ^a   Scalia, G ^a   Del Vecchio, L ^a   Ferrara, F ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Hairy cell leukemia; Rituximab

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG RESPONSE; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA CELL; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; CLADRIBINE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, HAIRY CELL; MALE; PENTOSTATIN; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 0036959124     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0559-z     Document Type: Article

References (10)

1. Cheson BD, Sorensen M, Vena AD, Montello MJ, Barrett JA, Admission E, Tillman M, Anion L, Connors J, Coiffure B, Lauria F (1999) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of The National Cancer Institute: a report of 979 patients. J Clin Oncol 16:3007-3015
2. Coiffier B (1999) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. Haematologica 84:14-18
3. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D (1999) Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br J Haematol 106:515-519
4. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D (1998) Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Pathol 51:364-369
5. Hagberg H, Lundholm L (2001) Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Br J Haematol 115:609-611
6. Hoffman M, Auerbach L (2000) Bone marrow remission of hairy cell leukemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 109:900-901
7. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Hematologica 86:1046-1050
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
9. Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia following cladribine treatment. Blood 92:1918-1926
10. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S (2000) Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 22:3875-3877